UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 86

Sortiert nach

Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development

Journal of medicinal chemistry, 2013-07, Vol.56 (14), p.5979-5983

2013

Link zum Volltext

Verfügbarkeit prüfen

Stapled α−helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy

Proceedings of the National Academy of Sciences - PNAS, 2013-09, Vol.110 (36), p.E3445-E3454

2013

Link zum Volltext

Verfügbarkeit prüfen

MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8), p.2587-2597

2013

Link zum Volltext

Verfügbarkeit prüfen

Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer

Cancer research (Chicago, Ill.), 2012-02, Vol.72 (3), p.779-789

2012

Link zum Volltext

Verfügbarkeit prüfen

Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development

ACS medicinal chemistry letters, 2013-05, Vol.4 (5), p.466-469

2013

Link zum Volltext

Verfügbarkeit prüfen

RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis

Molecular cancer therapeutics, 2016-05, Vol.15 (5), p.946-957

2016

Link zum Volltext

Verfügbarkeit prüfen

Small-Molecule MDM2 Antagonists Reveal Aberrant P53 Signaling in Cancer: Implications for Therapy

Proceedings of the National Academy of Sciences - PNAS, 2006-02, Vol.103 (6), p.1888-1893

2006

Link zum Volltext

Verfügbarkeit prüfen

BRAFV600E negatively regulates the AKT pathway in melanoma cell lines

PloS one, 2012-08, Vol.7 (8), p.e42598

2012

Link zum Volltext

Verfügbarkeit prüfen

Discovery of siRNA Lipid Nanoparticles to Transfect Suspension Leukemia Cells and Provide In Vivo Delivery Capability

Molecular therapy, 2014-02, Vol.22 (2), p.359-370

2014

Link zum Volltext

Verfügbarkeit prüfen

Mesenchymal stem cells in early entry of breast cancer into bone marrow

PloS one, 2008-06, Vol.3 (6), p.e2563-e2563

2008

Link zum Volltext

Verfügbarkeit prüfen

Vitamin D3 receptor ablation alters mammary gland morphogenesis

Development (Cambridge), 2002-07, Vol.129 (13), p.3067-3076

2002

Link zum Volltext

Verfügbarkeit prüfen

Discovery of Potent and Orally Active p53-MDM2 Inhibitors RO5353 and RO2468 for Potential Clinical Development

ACS medicinal chemistry letters, 2014-02, Vol.5 (2), p.124-127

2014

Link zum Volltext

Verfügbarkeit prüfen

RG7212 Anti-TWEAK mAb Inhibits Tumor Growth through Inhibition of Tumor Cell Proliferation and Survival Signaling and by Enhancing the Host Antitumor Immune Response

Clinical cancer research, 2013-10, Vol.19 (20), p.5686-5698

2013

Link zum Volltext

Verfügbarkeit prüfen

Allosteric antibody inhibition of human hepsin protease

Biochemical journal, 2012-03, Vol.442 (3), p.483-494

2012

Link zum Volltext

Verfügbarkeit prüfen

In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials

Molecular cancer therapeutics, 2006-11, Vol.5 (11), p.2644-2658

2006

Link zum Volltext

Verfügbarkeit prüfen

MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer

Molecular cancer, 2011-05, Vol.10 (1), p.49-49, Article 49

2011

Link zum Volltext

Verfügbarkeit prüfen

Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis

Molecular cancer therapeutics, 2020-10, Vol.19 (10), p.2044-2056

2020

Link zum Volltext

Verfügbarkeit prüfen

Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation

Cancer research (Chicago, Ill.), 2011-08, Vol.71 (16), p.5535-5545

2011

Link zum Volltext

Verfügbarkeit prüfen

A T-cell–redirecting bispecific G-protein–coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma

Blood, 2020-04, Vol.135 (15), p.1232-1243

2020

Link zum Volltext

Verfügbarkeit prüfen

Novel Regimens of Capecitabine Alone and Combined with Irinotecan and Bevacizumab in Colorectal Cancer Xenografts

Anticancer research, 2009-01, Vol.29 (1), p.91-98

2009

Link zum Volltext

Verfügbarkeit prüfen

RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models

Cancer research (Chicago, Ill.), 2010-07, Vol.70 (13), p.5518-5527

2010

Link zum Volltext

Verfügbarkeit prüfen

Discovery of Sulanemadlin (ALRN-6924), the First Cell-Permeating, Stabilized α‑Helical Peptide in Clinical Development

Journal of medicinal chemistry, 2023-07, Vol.66 (14), p.9401-9417

2023

Link zum Volltext

Verfügbarkeit prüfen

Antitumor Activity of Capecitabine and Bevacizumab Combination in a Human Estrogen Receptor-negative Breast Adenocarcinoma Xenograft Model

Anticancer research, 2007-07, Vol.27 (4B), p.2279-2287

2007

Link zum Volltext

Verfügbarkeit prüfen

Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity

Molecular cancer therapeutics, 2021-12, Vol.20 (12), p.2317-2328

2021

Link zum Volltext

Verfügbarkeit prüfen

Teclistamab is an active T cell–redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma

Blood advances, 2020-09, Vol.4 (18), p.4538-4549

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 86

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(85)
Mit Volltextzugriff
(83)

Publikationsform

Artikel
(85)
Dissertationen
(1)

Sprache

Englisch
(86)
Japanisch
(13)

Erscheinungsjahr

n.n

Thema

Science & Technology
(46)
Life Sciences & Biomedicine
(42)
Humans
(39)
Animals
(35)
Mice
(31)
Oncology
(26)
Cell Line, Tumor
(23)
Xenograft Model Antitumor Assays
(18)
Biological And Medical Sciences
(16)
Medical Sciences
(16)
Female
(15)
Tumors
(15)
Mice, Nude
(14)
Antineoplastic Agents - Pharmacology
(13)
Pharmacology & Pharmacy
(12)
Pharmacology. Drug Treatments
(11)
Antineoplastic Agents
(10)
Cancer
(9)
Chemistry, Medicinal
(9)
Mutation
(9)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development

Stapled α−helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy

MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models

Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer

Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development

RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis

Small-Molecule MDM2 Antagonists Reveal Aberrant P53 Signaling in Cancer: Implications for Therapy

BRAFV600E negatively regulates the AKT pathway in melanoma cell lines

Discovery of siRNA Lipid Nanoparticles to Transfect Suspension Leukemia Cells and Provide In Vivo Delivery Capability

Mesenchymal stem cells in early entry of breast cancer into bone marrow

Vitamin D3 receptor ablation alters mammary gland morphogenesis

Discovery of Potent and Orally Active p53-MDM2 Inhibitors RO5353 and RO2468 for Potential Clinical Development

RG7212 Anti-TWEAK mAb Inhibits Tumor Growth through Inhibition of Tumor Cell Proliferation and Survival Signaling and by Enhancing the Host Antitumor Immune Response

Allosteric antibody inhibition of human hepsin protease

In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials

MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer

Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis

Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation

A T-cell–redirecting bispecific G-protein–coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma

Novel Regimens of Capecitabine Alone and Combined with Irinotecan and Bevacizumab in Colorectal Cancer Xenografts

RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models

Discovery of Sulanemadlin (ALRN-6924), the First Cell-Permeating, Stabilized α‑Helical Peptide in Clinical Development

Antitumor Activity of Capecitabine and Bevacizumab Combination in a Human Estrogen Receptor-negative Breast Adenocarcinoma Xenograft Model

Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity

Teclistamab is an active T cell–redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma

Suchergebnisse filtern